Heart failure (HF) entails a poor prognosis, and sodium–glucose cotransporter (SGLT) type 2 (SGLT2) inhibitors (SGLT2is) are now among the pillars for its prevention and treatment. The gene discussed is SLC5A2; the disease is heart failure.